Pfizer and BioNTech Commence Phase 1/2 trial of Experimental COVID-19 Vaccine in the US

May 06, 2020 12:26 PM AEST | By Team Kalkine Media

Google News:

Recent News

Visa's Security Roadmap calls time on outdated security as AI-driven s...

Emeren Group Announces North America Management Change and Preliminary...

NECC Selects MedMinder to Transform Their Medication Management for In...

Smart Home Device Market Become USD 707.2 Billion Industry by 2032 Exh...

Two healthcare sector companies Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) revealed that the first participants in the Phase 1/2 clinical trial for the vaccine of BioNTech BNT162 to prevent coronavirus infection, have been dosed in the United States.

Moreover, this study is part of a global development program and is designed for the establishment of the safety, immunogenicity as well as the optimum dose level of four mRNA vaccine candidates which will be assessed in a single, continuous clinical study.

In Germany, the dosing of the first cohort of this developmental program was completed last week.

Pfizer also disclosed that this development program includes four vaccine candidates and each candidate indicating a different combination of mRNA format and target antigen.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.